Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) have been assigned a consensus rating of “Hold” from the six research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $5.00.

SNSS has been the subject of several analyst reports. Zacks Investment Research upgraded Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a report on Thursday, August 24th. Cantor Fitzgerald restated a “hold” rating and set a $3.00 price target on shares of Sunesis Pharmaceuticals in a report on Wednesday, September 27th. ValuEngine downgraded Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Cowen Inc restated a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. Finally, UBS AG initiated coverage on Sunesis Pharmaceuticals in a report on Monday. They set an “outperform” rating for the company.

Sunesis Pharmaceuticals (SNSS) traded down $0.13 on Tuesday, reaching $2.91. The company’s stock had a trading volume of 122,000 shares, compared to its average volume of 121,680. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of -0.34. Sunesis Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $4.45.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). During the same period last year, the company posted ($0.62) earnings per share. equities analysts predict that Sunesis Pharmaceuticals will post -1.58 earnings per share for the current year.

In other news, Director Dayton Misfeldt bought 400,000 shares of the company’s stock in a transaction on Friday, October 27th. The shares were acquired at an average cost of $2.00 per share, with a total value of $800,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Mpm Oncology Impact Management bought 25,300 shares of the company’s stock in a transaction on Thursday, November 2nd. The stock was purchased at an average cost of $2.59 per share, for a total transaction of $65,527.00. The disclosure for this purchase can be found here. Insiders have bought 506,800 shares of company stock valued at $1,091,282 over the last 90 days. Corporate insiders own 10.21% of the company’s stock.

Large investors have recently made changes to their positions in the business. Virtu KCG Holdings LLC purchased a new position in Sunesis Pharmaceuticals in the second quarter worth about $208,000. Balyasny Asset Management LLC purchased a new position in Sunesis Pharmaceuticals in the second quarter worth about $5,400,000. Wells Fargo & Company MN boosted its position in Sunesis Pharmaceuticals by 127.6% in the third quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 53,396 shares during the last quarter. Sphera Funds Management LTD. boosted its position in Sunesis Pharmaceuticals by 54.6% in the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 68,212 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Sunesis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 23,819 shares during the last quarter. 39.43% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Analysts Set Sunesis Pharmaceuticals, Inc. (SNSS) Price Target at $3.00” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/24/analysts-set-sunesis-pharmaceuticals-inc-snss-price-target-at-3-00.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Stock Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.